The shares of the Penny stock specializing in manufacturing and marketing a wide range of pharmaceutical formulations, hit a 5 percent upper circuit upon receiving two export sourcing orders valued at approximately Rs. 85.6 crore (Rs. 42.8 crore each).
With a market capitalization of Rs. 153.02 crores on Monday, the shares of Welcure Drugs & Pharmaceuticals Limited hit a 5 percent upper circuit, making a high of Rs. 13.60 per share compared to its previous closing price of Rs. 12.96 per share.
Welcure Drugs & Pharmaceuticals Limited, engaged in manufacturing and marketing a wide range of pharmaceutical formulations, has announced the execution of two significant export-sourcing assignments valued at approximately Rs. 85.6 crore with overseas counterparties Giant Exim and Ravina International.
Both orders pertain to the procurement and consolidation of mycorrhizal inoculant in bulk bags on an EXW basis, each worth around Rs. 42.8 crore. The company clarified that these transactions will generate fee-based revenue without exposing Welcure to inventory or logistics risks, thereby positively impacting margins in the current quarter, as commission income will be recognized upon dispatch of each lot.
Furthermore, Welcure is actively engaged in advanced discussions with additional international buyers and anticipates securing further export-sourcing mandates worth at least Rs. 20 crores within the ongoing quarter.
Financials & Others
The company’s revenue rose by 38,433 percent from Rs. 0.06 crore to Rs. 23.12 crore in Q4FY24-25. Meanwhile, the Net loss from Rs. 0.02 crore turned to a profit of Rs. 2.54 crore during the same period.
Welcure Drugs & Pharmaceuticals Ltd. is an Indian pharmaceutical company that was incorporated in 1992. The company is involved in the manufacturing and marketing of pharmaceutical formulations, including tablets, capsules, dry syrups, and various drug categories. Welcure Drugs & Pharmaceuticals Ltd. is headquartered in New Delhi, India.
Their state‑of‑the‑art manufacturing facility in Bhiwadi, Rajasthan, complies with ISO‑9002 and WHO‑GMP standards, featuring captive power, pollution control, and comprehensive in‑house testing
Recently, the company secured a Rs. 517 crore fee‑based sourcing and procurement mandate with Thailand’s Fortune Sagar Impex, which is expected to generate ₹25.85 crore in service income for FY 2025‑26, boosting its margins without increasing balance sheet risk.
Written by Sridhar J
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
